Literature DB >> 24418199

An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: is tumor size significance being underrated?

Alejandro M Aragona1, Nicasio A Cuneo2, Alejandro H Soderini2, Elsa B Alcoba3.   

Abstract

OBJECTIVE: To assess independent prognostic factors described in the literature. Thus, to identify different risk groups.
METHODS: Review of the records with a diagnosis of primary vulvar squamous cell carcinoma (January/1992-January/2012). INCLUSION CRITERIA: depth of stromal invasion (DSI) >1mm, pathological tumor size >2 cm, and pathological tumor-free margin ≥ 8 mm. Patients who underwent neoadjuvant therapy due to locoregionally advanced vulvar cancer were excluded. All the patients underwent radical, both local and regional, surgery. Adjuvant radiation therapy was administered to all patients with positive nodes. Features of lymph nodes, tumor size, age, grade, lymphovascular space invasion (LVSI), DSI, type of radical surgery, pathological margin distance and stage were evaluated by univariate and multivariate analysis.
RESULTS: 194 patients were included. Median age: 67 years. Median follow-up: 62 months. 5-year OS and DFS: 65.5% and 58.2%. Positive lymph nodes were found in 91 (46.9%) patients. After a multivariate analysis, the number of positive lymph nodes, extra-nodal growth, pathologic tumor size and DSI proved to be independent prognostic factors. A high risk group for failure to survive (5y-OS 24%) was identified: tumor size ≥ 6-7.9 cm and DSI >4mm or ≥ 8 cm irrespective of DSI; and extra-nodal growth or ≥2 positive lymph nodes irrespective of tumor size and DSI.
CONCLUSIONS: A new high-risk group was identified based on different cutoff values for tumor size, extra-nodal growth and number of positive lymph nodes. This could be very important in the tailored treatment of a specific group of patients with bulky primary tumors and a poorer prognosis.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Prognostic factors; Survival; Vulvar cancer

Mesh:

Year:  2014        PMID: 24418199     DOI: 10.1016/j.ygyno.2013.12.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Vulvar cancer: a review for dermatologists.

Authors:  Anastasiya Atanasova Chokoeva; Georgi Tchernev; Elena Castelli; Elisabetta Orlando; Shyam B Verma; Markus Grebe; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2015-05-01

2.  Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins.

Authors:  Sabrina M Bedell; Chloe Hedberg; Anna Griffin; Hannah Pearson; Annelise Wilhite; Nathan Rubin; Britt K Erickson
Journal:  Gynecol Oncol       Date:  2019-06-03       Impact factor: 5.482

3.  Diagnosis, Therapy and Follow-up Care of Vulvar Cancer and its Precursors. Guideline of the DGGG and DKG (S2k-Level, AWMF Registry Number 015/059, November 2015.

Authors:  H G Schnürch; S Ackermann; C D Alt; J Barinoff; C Böing; C Dannecker; F Gieseking; A Günthert; P Hantschmann; L C Horn; R Kürzl; P Mallmann; S Marnitz; G Mehlhorn; C C Hack; M C Koch; U Torsten; W Weikel; L Wölber; M Hampl
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

Review 4.  Advanced Vulvar Cancers: What are the Best Options for Treatment?

Authors:  Alejandro Soderini; Alejandro Aragona; Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2016-10       Impact factor: 5.075

5.  Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Masayuki Futagami; Yoshihito Yokoyama; Kaori Iino; Masahiko Aoki; Tadahiro Shoji; Toru Sugiyama; Hisanori Ariga; Hideki Tokunaga; Tadao Takano; Yoh Watanabe; Nobuo Yaegashi; Keiichi Jingu; Naoki Sato; Yukihiro Terada; Akira Anbai; Tsuyoshi Ohta; Hirohisa Kurachi; Yuuki Kuroda; Hiroshi Nishiyama; Keiya Fujimori; Takafumi Watanabe; Hisashi Sato; Toru Tase; Hitoshi Wada; Hideki Mizunuma
Journal:  Int J Clin Oncol       Date:  2015-02-24       Impact factor: 3.402

6.  Observational multicenter Italian study on vulvar cancer adjuvant radiotherapy (OLDLADY 1.2): a cooperation among AIRO Gyn, MITO and MaNGO groups.

Authors:  Gabriella Macchia; Calogero Casà; Martina Ferioli; Valentina Lancellotta; Donato Pezzulla; Brigida Pappalardi; Concetta Laliscia; Edy Ippolito; Jacopo Di Muzio; Alessandra Huscher; Francesca Tortoreto; Mariangela Boccardi; Roberta Lazzari; Pierandrea De Iaco; Francesco Raspagliesi; Angiolo Gadducci; Giorgia Garganese; Gabriella Ferrandina; Alessio Giuseppe Morganti; Luca Tagliaferri
Journal:  Radiol Med       Date:  2022-09-10       Impact factor: 6.313

Review 7.  [Grading of gynecological tumors : Current aspects].

Authors:  L-C Horn; D Mayr; C E Brambs; J Einenkel; I Sändig; K Schierle
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

8.  Vulvar cancer in the north of Israel.

Authors:  Orit Kaidar-Person; Nour Ibrahim; Amnon Amit; Roxolyana Bortnyak-Abdah
Journal:  Rambam Maimonides Med J       Date:  2014-07-25

9.  Defining the concept of locally advanced squamous cell carcinoma of the vulva: a new perspective based on standardization of criteria and current evidence.

Authors:  Alejandro M Aragona; Alejandro H Soderini; Nicasio A Cuneo
Journal:  J Gynecol Oncol       Date:  2014-07-06       Impact factor: 4.401

10.  Interstitial high-dose-rate brachytherapy in locally advanced and recurrent vulvar cancer.

Authors:  Sylwia Kellas-Ślęczka; Brygida Białas; Marek Fijałkowski; Piotr Wojcieszek; Marta Szlag; Agnieszka Cholewka; Maciej Ślęczka; Zofia Kołosza
Journal:  J Contemp Brachytherapy       Date:  2016-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.